Amicus Therapeutics Stock News

Amicus Therapeutics Inc (NASDAQ: FOLD) has announced additional results from a Phase 1/2 clinical study of AT-GAA in adult patients with Pompe disease. Study participants treated with AT-GAA for up

PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will

The trading price of Amicus Therapeutics Inc. (NASDAQ:FOLD) floating higher at last check on Wednesday, March 09, closing at $9.05, 8.19% higher than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it … Amicus Therapeutics Inc.’s Stock Gains 8.19%, But It May Still Be Worth Investing In. Read More »

PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Cowen 42 nd Annual Health Care Conference on Tuesday, March 8, 2022 at 9:10 a.m. E.T.

Global Batten Disease Drug Pipeline Market Research Report provides key analysis on the market status of the Batten Disease Drug Pipeline with the best facts and figures, meaning, definition, SWOT analysis, expert opinions, and the latest developments across the globe.

Amicus Therapeutics called off a planned spinout of its gene therapy division via a combination with a SPAC, spelling more trouble for the gene therapy field.

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -107.14% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock

Amicus Therapeutics' (FOLD) CEO John Crowley on Q4 2021 Results - Earnings Call Transcript

Amicus Therapeutics Inc (NASDAQ: FOLD ) has terminated its plans to spin off its gene therapy assets, citing ''existing market conditions.'' With "market conditions" sinking the planned merger with A RYA Sciences Acquisition Corp IV (NASDAQ: ARYD ), Amicus plans to prioritize its gene therapy pipeline as part of a push to generate $400 million in net savings through 2026. By merging its gene therapy unit with Perceptive Advisors'' ARYA Sciences Acquisition Corp IV, Amicus planned to reduce … Full story available on Benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th

ARYA Sciences Acquisition Corp IV (ARYD) and Amicus Therapeutics (FOLD) mutually agreed to terminate their previously announced business combination agreement due to existing…

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -107.14% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.